



PHARMA CBD SPAC

AVAILABLE FOR PRE-IPO INVESTMENT
(Sponsoring)



SHANDA CONSULT

THE STRATEGY OF LENUS BIOSCIENCE SPAC



CREATE VALUE

LENUS BIOSCIENCE SPAC targets to acquire a conglomerate of companies in the area of medical cannabis (R&D, pharmaceutical production, distribution of pharmaceutical products that create synergies and bring new technologies and a new approach in their business combination together.

BIOTECH, NANOTECH AND MEDICAL CBD/THC

We believe, that each of these three areas holds significant growth potential and that our team will indeed succeed building a company that combines those areas.

PROVEN EXPERTS

Experts from the financial business and the biotech industry will together evaluate companies to acquire at least 200% to 400% of the IPO proceeds in enterprise value.

LENUS NANO - BIOTECH

LENUS IS A MEDICAL BIOTECH PROJECT

- dealing with drug nanospheres and medical cannabis.

WE ARE DEDICATED TO ADVANCE LENUS TO A SUCCESSFUL IPO

- Using a Special Purpose Acquisition Company we focus on the acquisition of promising companies with forward-looking technologies in the pharmaceutical sector, have experience in medical CBD/THC R&D.

IT IS OUR OUTSTANDING VISION TO CREATE IMPACT ON THE MARKET

- Nano-Biotech plus CBD /THC will create new drugs and improve the efficiency of proven active ingredients.

IT IS OUR STRATEGY TO ACQUIRE POTENTIAL AND CREATE SYNERGIES

- Acquiring and/or cooperating with companies that have proven track record in related R&D or are hidden champions in the pharmaceutical market.

PEOPLE MAKE THE DIFFERENCE

- We work together with experts and institutions who are enthusiastic about making this project a success and who want to pass on their long-standing expertise.

CONSENSUS ON GROWTH POTENTIAL

Expecting medical cannabis having a share of one-third of the gross market of legal cannabis and legal cannabis hitting \$61 billion, this would result in a **\$20 billion market for medical cannabis** worldwide.

New Frontier Data bases these projections on the markets that have already passed such legal initiatives and don't include additional states that could come on board in 2019, e.g. Texas and Wisconsin neither, that regarding legalization in the European Union or elsewhere in the world.

With a budget of \$1.3 trillion in health care spending, European government-subsidized health care systems will bring the medical cannabis market to **dominate Europe and become the largest medical marijuana market** in the world.

Germany is poised to be the leader of the European cannabis market, and **Italy** is expected to be second with \$1.2 billion in sales by 2027; **Cyprus** may produce €235m worth of medicinal cannabis every year.

AVAILABLE FOR PRE-IPO INVESTMENT: **LENUS**



Industry

Medical Cannabis



IPO Target

USD 90 to 150 million *(variable)*



Pre-IPO Investment

USD 4,5 to 7,5 million



Thereof committed

USD 4.500.000



Status

S1-Filing

Co-Sponsoring still possible

Description:

Targets to acquire a conglomerate of companies in the area of medical cannabis (R&D, pharmaceutical production, distribution of pharmaceutical products), which create synergies and bring new technologies and a new approach in their business combination together.

INTERESTED AND WANT TO KNOW MORE?

Please ask us for further information:



Stefan Nolte

E: stefan.nolte@shandaconsult.com

T: +357 222 72 300

shandaconsult.com